Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
CNS Drugs
Erschienen in: CNS Drugs 7/2008

01.07.2008 | Therapy In Practice

Pathological Laughing and Crying

Epidemiology, Pathophysiology and Treatment

verfasst von: Hal S. Wortzel, Timothy J. Oster, C. Alan Anderson, Dr David B. Arciniegas

Erschienen in: CNS Drugs | Ausgabe 7/2008

Einloggen, um Zugang zu erhalten

Abstract

Pathological laughing and crying (PLC) is characterized by frequent, brief, intense paroxysms of uncontrollable crying and/or laughing due to a neurological disorder. When sufficiently frequent and severe, PLC may interfere with the performance of activities of daily living, interpersonal functioning, or both, and is a source of distress for affected patients and their families. PLC is also often misunderstood by patients and their families, and is under-recognized by the clinicians caring for patients with this disorder. However, this syndrome is easily recognized when understood properly and is highly responsive to treatment with a variety of pharmacological agents.
This review aims to facilitate the diagnosis and treatment of patients with PLC, and begins by providing definitions of mood and affect that will help clinicians distinguish between mood disorders, such as major depression and mania, and disorders of affect, such as PLC. In addition, the various terms used to describe this syndrome are reviewed and a recommendation for the use of the term PLC is made. The core clinical features of PLC are also presented and the epidemiology of this syndrome is reviewed. A discussion of the pathophysiology of PLC, including the neuroanatomic and neurochemical bases, is provided. Finally, the evaluation and treatment of patients with PLC is described.
Based on the pathophysiology of PLC and on a detailed review of published treatment studies, SSRIs are recommended as first-line pharmacotherapy for this disorder. When SSRIs are ineffective or poorly tolerated, other treatment options, including TCAs, noradrenergic reuptake inhibitors, novel antidepressants, dopaminergic agents and uncompetitive NMDA receptor antagonists may be useful second-line treatments.
Literatur
1.
Arciniegas DB, Topkoff J. The neuropsychiatry of pathologic affect: an approach to valuation and treatment. Semin Clin Neuropsychiatry 2000 Oct; 5(4): 290–306PubMedCrossRef
2.
Wilson SAK. Some problems in neurology: no. II. Pathological laughing and crying. J Neurol Psychopathol 1924; 4(16): 299–333CrossRef
3.
Schiffer RB, Herndon RM, Rudick RA. Treatment of pathologic laughing and weeping with amitriptyline. N Engl J Med 1985; 312(23): 1480–2PubMedCrossRef
4.
Cummings JL, Arciniegas DB, Brooks BR, et al. Defining and diagnosing involuntary emotional expression disorder. CNS Spectr 2006 Jun; 11(6): 1–7PubMed
5.
Rabins PV, Arciniegas DB. Pathophysiology of involuntary emotional expression disorder. CNS Spectr 2007 Apr; 12(4 Suppl. 5): 17–22PubMed
6.
Parvizi J, Arciniegas DB, Bernardini GL, et al. Diagnosis and management of pathological laughter and crying. Mayo Clin Proc 2006 Nov; 81(11): 1482–6PubMedCrossRef
7.
Parvizi J, Anderson SW, Martin CO, et al. Pathological laughter and crying: a link to the cerebellum. Brain 2001 Sep; 124 (Pt 9): 1708–19PubMedCrossRef
8.
Calvert T, Knapp P, House A. Psychological associations with emotionalism after stroke. J Neurol Neurosurg Psychiatry 1998 Dec; 65(6): 928–9PubMedCrossRef
9.
Brooks BR. Involuntary emotional expression disorder: treating the untreated. CNS Spectr 2007 Apr; 12(4 Suppl. 5): 23–7PubMed
10.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000
11.
Arciniegas DB. A clinical overview of pseudobulbar affect. Am J Geriatr Pharmacother 2005; 3Suppl. A: 4–8PubMedCrossRef
12.
Feinstein A, Feinstein K, Gray T, et al. Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. Arch Neurol 1997 Sep; 54(9): 1116–21PubMedCrossRef
13.
Schiffer R, Pope LE. Review of pseudobulbar affect including a novel and potential therapy. J Neuropsychiatry Clin Neurosci 2005; 17(4): 447–54PubMedCrossRef
14.
Zeilig G, Drubach DA, Katz-Zeilig M, et al. Pathological laughter and crying in patients with closed traumatic brain injury. Brain Inj 1996; 10(8): 591–7PubMedCrossRef
15.
Tateno A, Jorge RE, Robinson RG. Pathological laughing and crying following traumatic brain injury. J Neuropsychiatry Clin Neurosci 2004; 16(4): 426–34PubMedCrossRef
16.
House A, Dennis M, Molyneux A, et al. Emotionalism after stroke. BMJ 1989 Apr; 298(6679): 991–4PubMedCrossRef
17.
Kim JS. Pathological laughter and crying in unilateral stroke. Stroke 1997 Nov; 28(11): 2321PubMed
18.
Robinson RG, Parikh RM, Lipsey JR, et al. Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. Am J Psychiatry 1993 Feb; 150(2): 286–93PubMed
19.
Gallagher JP. Pathologic laughter and crying in ALS: a search for their origin. Acta Neurol Scand 1989 Aug; 80(2): 114–7PubMedCrossRef
20.
Gubbay SS, Kahana E, Zilber N, et al. Amyotrophic lateral sclerosis: a study of its presentation and prognosis. J Neurol 1985; 232(5): 295–300PubMedCrossRef
21.
Tariot PN, Mack JL, Patterson MB, et al. The behavior rating scale for dementia of the Consortium to Establish a Registry for Alzheimer’s Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer’s Disease. Am J Psychiatry 1995 Sep; 152(9): 1349–57
22.
Haupt M. Emotional lability, intrusiveness, and catastrophic reactions. Int Psychogeriatr 1996; 8 Suppl. 3: 409–14
23.
Starkstein SE, Migliorelli R, Teson A, et al. Prevalence and clinical correlates of pathological affective display in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1995 Jul; 59(1): 55–60PubMedCrossRef
24.
Loeb C, Poggio GF. Neural substrates of memory, affective functions, and conscious experience. Adv Anat Embryol Cell Biol 2002; 166: 1–111PubMedCrossRef
25.
Damasio AR, Grabowski TJ, Bechara A, et al. Subcortical and cortical brain activity during the feeling of self-generated emotions. Nat Neurosci 2000 Oct; 3(10): 1049–56PubMedCrossRef
26.
Lane RD, Reiman EM, Bradley MM, et al. Neuroanatomical correlates of pleasant and unpleasant emotion. Neuropsychologia 1997 Nov; 35(11): 1437–44PubMedCrossRef
27.
Lane RD, Reiman EM, Ahern GL, et al. Neuroanatomical correlates of happiness, sadness, and disgust. Am J Psychiatry 1997 Jul; 154(7): 926–33PubMed
28.
Phillips ML, Drevets WC, Rauch SL, et al. Neurobiology of emotion perception: I. The neural basis of normal emotion perception. Biol Psychiatry 2003 Sep 1; 54(5): 504–14
29.
Arciniegas DB, Lauterbach EC, Anderson KE, et al. The differential diagnosis of pseudobulbar affect (PBA): distinguishing PBA among disorders of mood and affect. Proceedings of a roundtable meeting. CNS Spectr 2005 May; 10(5): 1–14
30.
Schmahmann JD, Caplan D. Cognition, emotion and the cerebellum. Brain 2006 Feb; 129 (Pt 2): 290–2PubMedCrossRef
31.
Schmahmann JD, Sherman JC. The cerebellar cognitive affective syndrome. Brain 1998 Apr; 121 (Pt 4): 561–79PubMedCrossRef
32.
Schmahmann JD. An emerging concept: the cerebellar contribution to higher function. Arch Neurol 1991 Nov; 48(11): 1178–87PubMedCrossRef
33.
Parvizi J, Schiffer R. Exaggerated crying and tremor with a cerebellar cyst. J Neuropsychiatry Clin Neurosci 2007; 19(2): 187–90PubMedCrossRef
34.
Parvizi J, Joseph J, Press DZ, et al. Pathological laughter and crying in patients with multiple system atrophy-cerebellar type. Mov Disord 2007 Apr 30; 22(6): 798–803PubMedCrossRef
35.
Plutchik R. A general psychoevolutionary theory of emotion. In: Plutchik R, Kellerman H, editors. Emotion: theory, research, and experience. Vol. 1. Theories of emotion. New York: Academic, 1980: 3–33
36.
Ekman P. Emotion in the human face. New York: Cambridge University Press, 1982
37.
Phan KL, Wager T, Taylor SF, et al. Functional neuroanatomy of emotion: a meta-analysis of emotion activation studies in PET and fMRI. Neuroimage 2002 Jun; 16(2): 331–48PubMedCrossRef
38.
Sackeim HA, Greenberg MS, Weiman AL, et al. Hemispheric asymmetry in the expression of positive and negative emotions. Neurologic evidence. Arch Neurol 1982 Apr; 39(4): 210–8CrossRef
39.
Andersen G, Ingeman-Nielsen M, Vestergaard K, et al. Pathoanatomic correlation between poststroke pathological crying and damage to brain areas involved in serotonergic neurotransmission. Stroke 1994 May; 25(5): 1050–2PubMedCrossRef
40.
Derex L, Ostrowsky K, Nighoghossian N, et al. Severe pathological crying after left anterior choroidal artery infarct: reversibility with paroxetine treatment. Stroke 1997 Jul; 28(7): 1464–6PubMedCrossRef
41.
Murai T, Barthel H, Berrouschot J, et al. Neuroimaging of serotonin transporters in post-stroke pathological crying. Psychiatry Res 2003 Jul 30; 123(3): 207–11PubMedCrossRef
42.
Møller M, Andersen G, Gjedde A. Serotonin 5HT1a receptor availability and pathological crying after stroke. Acta Neurol Scand 2007 Aug; 116(2): 83–90PubMedCrossRef
43.
Møller M, Andersen G. Inhibition of selective noradrenergic reuptake as treatment of pathological laughter. J Clin Psychopharmacol 2007 Feb; 27(1): 108–10PubMedCrossRef
44.
Lauterbach EC, Schweri MM. Amelioration of pseudobulbar affect by fluoxetine: possible alteration of dopamine-related pathophysiology by a selective serotonin reuptake inhibitor. J Clin Psychopharmacol 1991 Dec; 11(6): 392–3PubMedCrossRef
45.
Evans RW, Gualtieri CT, Patterson D. Treatment of chronic closed head injury with psychostimulant drugs: a controlled case study and an appropriate evaluation procedure. J Nerv Ment Dis 1987 Feb; 175(2): 106–10PubMedCrossRef
46.
Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 2004 Oct 26; 63(8): 1364–70PubMedCrossRef
47.
Panitch HS, Thisted RA, Smith RA, et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol 2006 May; 59(5): 780–7PubMedCrossRef
48.
Kim SW, Shin IS, Kim JM, et al. Mirtazapine treatment for pathological laughing and crying after stroke. Clin Neuro-pharmacol 2005 Sep; 28(5): 249–51
49.
Linner L, Wiker C, Arborelius L, et al. Selective noradrenaline reuptake inhibition enhances serotonergic neuronal activity and transmitter release in the rat forebrain. J Neural Transm 2004 Feb; 111(2): 127–39PubMedCrossRef
50.
Taylor MJ, Freemantle N, Geddes JR, et al. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry 2006 Nov; 63(11): 1217–23PubMedCrossRef
51.
Sackeim HA, Roose SP, Burt T. Optimal length of antidepressant trials in late-life depression. J Clin Psychopharmacol 2005 Aug; 25(4 Suppl. 1): S34–7PubMedCrossRef
52.
Malberg JE, Blendy JA. Antidepressant action: to the nucleus and beyond. Trends Pharmacol Sci 2005 Dec; 26(12): 631–8PubMedCrossRef
53.
Donati RJ, Rasenick MM. G protein signaling and the molecular basis of antidepressant action. Life Sci 2003 May 23; 73(1): 1–17PubMedCrossRef
54.
55.
Chahine LM, Chemali Z. Du rire aux larmes: pathological laughing and crying in patients with traumatic brain injury and treatment with lamotrigine. Epilepsy Behav 2006 May; 8(3): 610–5PubMedCrossRef
56.
House AO, Hackett ML, Anderson CS, et al. Pharmaceutical interventions for emotionalism after stroke. Cochrane Database Syst Rev 2004; (2): CD003690
57.
Andersen G, Stylsvig M, Sunde N. Citalopram treatment of traumatic brain damage in a 6-year-old boy. J Neurotrauma 1999 Apr; 16(4): 341–4PubMedCrossRef
58.
Andersen G, Vestergaard K, Riis JO. Citalopram for post-stroke pathological crying. Lancet 1993 Oct 2; 342(8875): 837–9PubMedCrossRef
59.
Iannaccone S, Ferini-Strambi L. Pharmacologic treatment of emotional lability. Clin Neuropharmacol 1996 Dec; 19(6): 532–5PubMedCrossRef
60.
Muller U, Murai T, Bauer-Wittmund T, et al. Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Inj 1999 Oct; 13(10): 805–11PubMedCrossRef
61.
Tsai WC, Lai JS, Wang TG. Treatment of emotionalism with fluoxetine during rehabilitation. Scand J Rehabil Med 1998 Sep; 30(3): 145–9PubMedCrossRef
62.
Burns A, Russell E, Stratton-Powell H, et al. Sertraline in stroke-associated lability of mood. Int J Geriatr Psychiatry 1999 Aug; 14(8): 681–5PubMedCrossRef
63.
Murray V, von Arbin M, Bartfai A, et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. J Clin Psychiatry 2005 Jun; 66(6): 708–16PubMedCrossRef
64.
Mukand J, Kaplan M, Senno RG, et al. Pathological crying and laughing: treatment with sertraline. Arch Phys Med Rehabil 1996 Dec; 77(12): 1309–11PubMedCrossRef
65.
Nahas Z, Arlinghaus KA, Kotrla KJ, et al. Rapid response of emotional incontinence to selective serotonin reuptake inhibitors. J Neuropsychiatry Clin Neurosci 1998; 10(4): 453–5PubMed
66.
Benedek DM, Peterson KA. Sertraline for treatment of pathological crying. Am J Psychiatry 1995 Jun; 152(6): 953–4PubMed
67.
Seliger GM, Hornstein A. Serotonin, fluoxetine, and pseudobulbar affect [letter]. Neurology 1989 Oct; 39(10): 1400PubMedCrossRef
68.
Seliger GM, Hornstein A, Flax J, et al. Fluoxetine improves emotional incontinence. Brain Inj 1992 May; 6(3): 267–70PubMedCrossRef
69.
Brown KW, Sloan RL, Pentland B. Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatr Scand 1998 Dec; 98(6): 455–8PubMedCrossRef
70.
Sloan RL, Brown KW, Pentland B. Fluoxetine as a treatment for emotional lability after brain injury. Brain Inj 1992 Jul; 6(4): 315–9PubMedCrossRef
71.
Jeret JS. Treatment of poststroke pathological crying. Stroke 1997 Nov; 28(11): 2321–2PubMed
72.
Panzer MJ, Mellow AM. Antidepressant treatment of pathologic laughing or crying in elderly stroke patients. J Geriatr Psychiatry Neurol 1992 Oct; 5(4): 195–9PubMed
73.
Schmitt JA, Kruizinga MJ, Riedel WJ. Non-serotonergic pharmacological profiles and associated cognitive effects of serotonin reuptake inhibitors. J Psychopharmacol 2001 Sep; 15(3): 173–9PubMedCrossRef
74.
Deakin JB, Rahman S, Nestor PJ, et al. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl) 2004 Apr; 172(4): 400–8CrossRef
75.
Ivan TM, Franco K. Poststroke pathological laughing and crying. Am J Psychiatry 1994 Feb; 151(2): 290–1PubMed
76.
Schiffer RB, Cash J, Herndon RM. Treatment of emotional lability with low-dosage tricyclic antidepressants. Psychosomatics 1983 Dec; 24(12): 1094–6PubMedCrossRef
77.
Szczudlik A, Slowik A, Tomik B. The effect of amitriptyline on the pathological crying and other pseudobulbar signs [in Polish]. Neurol Neurochir Pol 1995 Sep; 29(5): 663–74PubMed
78.
Allman P. Drug treatment of emotionalism following brain damage. J R Soc Med 1992 Jul; 85(7): 423–4PubMed
79.
de Oliveira-Souza R, de Figueiredo WM, Andreiuolo PA. Pathological crying and unilateral pontine infarction [in Portuguese]. Arq Neuropsiquiatr 1995 Sep; 53(3-B): 680–9PubMedCrossRef
80.
Lawson IR, MacLeod RD. The use of imipramine (“Tofranil”) and other psychotropic drugs in organic emotionalism. Br J Psychiatry 1969 Mar; 115(520): 281–5PubMedCrossRef
81.
Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000; 403: 17–25PubMedCrossRef
82.
Rosenberg C, Lauritzen L, Brix J, et al. Citalopram versus amitriptyline in elderly depressed patients with or without mild cognitive dysfunction: a Danish multicentre trial in general practice. Psychopharmacol Bull 2007; 40(1): 63–73PubMed
83.
van Laar MW, van Willigenburg AP, Volkerts ER. Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects. J Clin Psychopharmacol 1995 Feb; 15(1): 30–40PubMedCrossRef
84.
Jiang W, Davidson JR. Antidepressant therapy in patients with ischemic heart disease. Am Heart J 2005 Nov; 150(5): 871–81PubMedCrossRef
85.
Murray JB. Cardiac disorders and antidepressant medications. J Psychol 2000 Mar; 134(2): 162–8PubMedCrossRef
86.
Roose SP. Considerations for the use of antidepressants in patients with cardiovascular disease. Am Heart J 2000 Oct; 140(4 Suppl.): 84–8PubMedCrossRef
87.
Swenson JR, Doucette S, Fergusson D. Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of randomized trials. Can J Psychiatry 2006 Dec; 51(14): 923–9PubMed
88.
Smith AG, Montealegre-Orjuela M, Douglas JE, et al. Venlafaxine for pathological crying after stroke. J Clin Psychiatry 2003 Jun; 64(6): 731–2PubMedCrossRef
89.
Ramasubbu R. Lamotrigine treatment for post-stroke pathological laughing and crying. Clin Neuropharmacol 2003 Sep; 26(5): 233–5PubMedCrossRef
90.
Wolf JK, Santana HB, Thorpy M. Treatment of “emotional incontinence” with levodopa. Neurology 1979 Oct; 29(10): 1435–6PubMedCrossRef
91.
Udaka F, Yamao S, Nagata H, et al. Pathologic laughing and crying treated with levodopa. Arch Neurol 1984 Oct; 41(10): 1095–6PubMedCrossRef
92.
Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 2001 Feb; 3(1): 22–7PubMedCrossRef
93.
94.
Pucci E, Branas P, D’Amico R, et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev 2007; (1): CD002818
95.
Taus C, Giuliani G, Pucci E, et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev 2003; (2): CD002818
96.
Drake Jr ME, Pakalnis A, Denio LS, et al. Amantadine hydrochloride for refractory generalized epilepsy in adults. Acta Neurol Belg 1991; 91(3): 159–64PubMed
97.
Shields WD, Lake JL, Chugani HT. Amantadine in the treatment of refractory epilepsy in childhood: an open trial in 10 patients. Neurology 1985 Apr; 35(4): 579–81PubMedCrossRef
98.
Shahar EM, Brand N. Effect of add-on amantadine therapy for refractory absence epilepsy. J Pediatr 1992 Nov; 121 (5 Pt 1): 819–21PubMedCrossRef
99.
Reis J, John D, Heimeroth A, et al. Modulation of human motor cortex excitability by single doses of amantadine. Neuropsy-chopharmacology 2006 Dec; 31(12): 2758–66CrossRef
100.
Mizoguchi K, Yokoo H, Yoshida M, et al. Amantadine increases the extracellular dopamine levels in the striatum by reuptake inhibition and by N-methyl-D-aspartate antagonism. Brain Res 1994 Oct 31; 662(1–2): 255–8PubMedCrossRef
101.
Jackisch R, Link T, Neufang B, et al. Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine: no evidence for direct dopaminomimetic or antimus-carinic properties. Arch Int Pharmacodyn Ther 1992 Nov; 320: 21–42PubMed
102.
Peeters M, Romieu P, Maurice T, et al. Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine. Eur J Neurosci 2004 Apr; 19(8): 2212–20PubMedCrossRef
103.
Tortella FC, Pellicano M, Bowery NG. Dextromethorphan and neuromodulation: old drug coughs up new activities. Trends Pharmacol Sci 1989 Dec; 10(12): 501–7PubMedCrossRef
104.
Klein M, Paturzo JJ, Musacchio JM. The effect of prototypic sigma ligands on the binding of [3H]dextromethorphan to guinea pig brain. Neurosci Lett 1989 Feb 13; 97(1–2): 175–80PubMedCrossRef
105.
Yamamoto H, Yamamoto T, Sagi N, et al. Sigma ligands indirectly modulate the NMDA receptor-ion channel complex on intact neuronal cells via sigma 1 site. J Neurosci 1995 Jan; 15 (1 Pt 2): 731–6PubMed
106.
Bermack JE, Debonnel G. The role of sigma receptors in depression. J Pharmacol Sci 2005 Mar; 97(3): 317–36PubMedCrossRef
107.
Bermack JE, Debonnel G. Distinct modulatory roles of sigma receptor subtypes on glutamatergic responses in the dorsal hippocampus. Synapse 2005 Jan; 55(1): 37–44PubMedCrossRef
108.
Bermack JE, Debonnel G. Modulation of serotonergic neurotransmission by short- and long-term treatments with sigma ligands. Br J Pharmacol 2001 Oct; 134(3): 691–9PubMedCrossRef
109.
Narita N, Hashimoto K, Tomitaka S, et al. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 1996 Jun 20; 307(1): 117–9PubMedCrossRef
110.
Dhir A, Kulkarni SK. Involvement of sigma-1 receptor modulation in the antidepressant action of venlafaxine. Neurosci Lett 2007 Jun 15; 420(3): 204–8PubMedCrossRef
Metadaten
Titel
Pathological Laughing and Crying
Epidemiology, Pathophysiology and Treatment
verfasst von
Hal S. Wortzel
Timothy J. Oster
C. Alan Anderson
Dr David B. Arciniegas
Publikationsdatum
01.07.2008
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 7/2008
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200822070-00001

Weitere Artikel der Ausgabe 7/2008

CNS Drugs 7/2008 Zur Ausgabe

Review Article

Impact of Newer Pharmacological Treatments on Quality of Life in Patients with Parkinson’s Disease

Original Research Article

Efficacy and Tolerability of Milnacipran in the Treatment of Major Depression in Comparison with Other Antidepressants

Original Research Article

Effect of Switching Drug Formulations from Immediate-Release to Extended-Release OROS Methylphenidate

Review Article

Antipsychotic-Induced Weight Gain in Chronic and First-Episode Psychotic Disorders

Adis Spotlight

Spotlight on Bupropion in Major Depressive Disorder

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise